Hepatitis B and Hepatitis C Reactivation in the Biologic Era.
Hepatitis B (HBV) and hepatitis C (HCV) reactivation may occur after the use of biologic agents. During the last decade, utilization of biologics has changed the fate of many treated for cancer, autoimmune and connective tissue disease, maintenance of transplanted organs, and the prevention of graft-versus-host disease among others. HBV reactivation has been reported in up to 50% of HBV carriers undergoing immunosuppressive therapy, and there is emerging data pointing towards an increased risk for HCV reactivation. If reactivation of HBV and HCV occurs, the spectrum of clinical manifestations can range from asymptomatic hepatitis flares to hepatic decompensation, fulminant hepatic failure, and death. Therefore, identifying patients at risk and early diagnosis are imperative to decrease significant morbidity and mortality. The purpose of this article is to review the pathophysiology of the reactivation of HBV and HCV infection in patients receiving biologic therapies and the approaches used to diagnose, prevent, and treat HBV and HCV reactivation.
Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, USA.
Lizza
L
Bojito-Marrero
Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, USA.
Nikolaos
N
Pyrsopoulos
Biologics; Hepatitis B reactivation; Hepatitis C reactivation; Immunosuppressive therapy; Prophylactic antiviral treatment